Massie Technology Group, Inc.
Patent Pending, AI Driven Retinal Imaging Platform. Fully Engineered, Validated and Ready for Manufacturing. Strong Management Team Experienced in Med-Tech/AI and Advanced Optics
July 20, 2026
Massie Technology Group, Inc. (MTG)
San Ramon, California, USA
Massie Technology Group, Inc. (MTG)
San Ramon, California, USA
Massie Technology Group Unveils APEX — A Breakthrough AI + Advanced Optics Retinal Imaging Platform
Massie Technology Group, Inc. (MTG) today announced the introduction of APEX, a patent‑pending retinal imaging platform that combines advanced precision optics with AI‑driven diagnostic capabilities. APEX is designed to redefine early detection and management of vision disorders and expand diagnostic insight into neurological, metabolic, and oncologic diseases identifiable through high‑resolution retinal imaging and Artificial Intelligence (AI).
APEX replaces outdated, inequitable imaging technologies that have remained largely unchanged for two decades and that frequently fail to capture accurate images in patients with darkly pigmented retinas. By integrating next‑generation optics with AI, APEX enables clinicians to deliver more accurate, inclusive, and accessible care.
Experienced Leadership and Strong Market Position
MTG is led by seasoned founders and senior executives with extensive experience in optics engineering, regulatory strategy, clinical operations, and commercialization. The company is supported by top-tier medical Key Opinion Leaders (KOLs) across the ophthalmology community. With scalable manufacturing and streamlined operational requirements, MTG presents a low‑execution‑risk opportunity for early investors. Founders have invested over $2.0 million of personal capital, positioning MTG to access a $2 billion Total Addressable Market (TAM).
MTG is led by seasoned founders and senior executives with extensive experience in optics engineering, regulatory strategy, clinical operations, and commercialization. The company is supported by top-tier medical Key Opinion Leaders (KOLs) across the ophthalmology community. With scalable manufacturing and streamlined operational requirements, MTG presents a low‑execution‑risk opportunity for early investors. Founders have invested over $2.0 million of personal capital, positioning MTG to access a $2 billion Total Addressable Market (TAM).
Commercial Outlook and Revenue Potential
Leveraging deep market knowledge and established distribution pathways, MTG projects approximately $150 million in high‑margin annual revenue within five years, with more than 20% derived from SaaS and disposable components.
Leveraging deep market knowledge and established distribution pathways, MTG projects approximately $150 million in high‑margin annual revenue within five years, with more than 20% derived from SaaS and disposable components.
Clinical Demand and Market Validation
APEX will launch with a focus on early disease detection in pediatric patients, including underserved communities where portable imaging and telemedicine access are essential. Adult diagnostic applications—including OCT—will follow.
APEX will launch with a focus on early disease detection in pediatric patients, including underserved communities where portable imaging and telemedicine access are essential. Adult diagnostic applications—including OCT—will follow.
MTG has generated strong interest among respected ophthalmic KOLs, many of whom have expressed intent to purchase APEX units and are actively collaborating with MTG to expand diagnostic applications. With clinical validation completed through founder investment, MTG anticipates commercial availability within one year.
About Massie Technology Group, Inc.
Massie Technology Group, Inc. develops advanced diagnostic imaging technologies that combine precision optics with AI to improve early disease detection and expand access to high‑quality vision and neurological care. MTG is headquartered in San Ramon, California.
Massie Technology Group, Inc. develops advanced diagnostic imaging technologies that combine precision optics with AI to improve early disease detection and expand access to high‑quality vision and neurological care. MTG is headquartered in San Ramon, California.
Key Management Team Members
Nathan Messinger
Chief Operating Officer
Massie Technology Group, Inc.
Lead Investor Contact
Lead Investor Contact
N.A. (Bert) Massie, PhD –
Founder, Chairman & CEO
Paul Rychwalski, MD – Chief Medical Officer – MTG, Inc.
Chief & Professor of Ophthalmology/Pediatrics
Univ. Nebraska, Omaha, NE
Fundraise Details
Fundraise DetailsThis section is only visible to registered investors. Log in or register as an accredited investor to view.
Ready to Ask For Funding for your company?
Post a Funding RequestKey Facts
- Industry
- {{model.industry | ffIndustry}}
- Location
- {{model.city_state}}
- Year Founded
- {{model.year_founded}}
- Monthly Income
- {{model.monthly_income | ffIncome}}
- Website
- {{model.homepage_url}}